PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
94.56%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 17.73%. Joel Greenblatt would see it as a clear outperformance relative to peers.
11.63%
D&A expands slightly while Drug Manufacturers - Specialty & Generic is negative at -0.01%. Peter Lynch might see peers pausing expansions more aggressively.
-202.02%
Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
6.78%
SBC growth of 6.78% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-620.50%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is -22.75%. Seth Klarman would see an advantage if sales remain robust.
-235.07%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
10.99%
Inventory growth of 10.99% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.
-1393.26%
AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
214.93%
Growth of 214.93% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
-112.88%
Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -11.11%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.
-1372.80%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is -2.71%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
24.61%
CapEx growth of 24.61% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
-100.00%
Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.
-100.00%
Investment purchases shrink yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.
323.81%
Proceeds growth of 323.81% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or certain maturities are driving this difference.
-112.16%
We reduce “other investing” yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a potential advantage in preserving cash if top-line growth is not harmed.
-1298.68%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
39.55%
Debt repayment growth of 39.55% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
100.00%
Issuance growth of 100.00% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.